ALX Oncology

ALX Oncology is a publicly traded, clinical-stage company based in South San Francisco, California. It is a small company with a workforce of 8 employees. ALX Oncology develops therapies that block the CD47 checkpoint pathway, aiming to enhance the immune system's ability to combat cancer. The company's primary product candidate, evorpacept, is a novel CD47 blocking therapeutic designed to bridge the innate and adaptive immune system responses. This therapy has shown encouraging clinical results in treating a variety of blood and solid cancers when used alongside other leading anticancer agents. Evorpacept sets itself apart due to its high-affinity CD47 binding domain and unique inactivated proprietary Fc domain, making it a next-generation CD47 blocking therapeutic. Further information about ALX Oncology can be found at www.alxoncology.com.